Charles Nichols
Professor of Pharmacology at Louisiana State University Health Sciences Center in New Orleans
Data updated
Research Footprint
Charles Nichols appears in 17 tracked papers (2015–2025), most studied alongside Psilocybin, LSD and 5-MeO-DMT, across Substance Use Disorders (SUD), Immunology & Inflammation and Depressive Disorders.
Most-cited paper: Psychedelics as Medicines: An Emerging New Paradigm (362 citations).
Frequent co-authors: David Nichols, Peter Hendricks and Robin Carhart-Harris.
Background & Research
Charles D. Nichols is a pharmacologist at LSU Health Sciences Center in New Orleans who has studied the cellular, molecular, genetic, and behavioral effects of psychedelics for more than 25 years. His work spans classic psychedelics, 5-MeO-DMT, LSD, and related compounds, with key contributions to understanding receptor pharmacology, brain signaling changes, and potential therapeutic mechanisms. He is also a founding member and current president of the International Society for Research on Psychedelics.
Key Impact
He is a leading psychedelic pharmacologist whose work has clarified 5-HT2A receptor biology, psychedelic-induced gene expression and plasticity, and anti-inflammatory mechanisms relevant to psychiatric and neurological therapeutics.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Charles Nichols is associated with.
Louisiana State University Health Sciences Center in New Orleans
Louisiana State University Health Sciences Center in New Orleans (LSU Health New Orleans) is an academic health sciences center in New Orleans, Louisiana, offering medical, dental, nursing, public health, allied health, and graduate education alongside clinical services and biomedical research.
View stakeholder →International Society for Research on Psychedelics
The International Society for Research on Psychedelics (ISRP) is a professional scientific society that connects researchers across disciplines to advance rigorous psychedelic science, collaboration, and dissemination.
View stakeholder →